ReviewTrends in immunology2024
Unmasking the hidden impact of viruses on tuberculosis risk.
Review in Trends in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Prevalence of Long COVID inJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Risk of incident tuberculosis after severe COVID-19: a nationwide cohort study.Nature communications · 2026Article
- Hepatitis C and risk of tuberculosis amongst United States veterans: a national cohort study.Lancet regional health. Americas · 2026Article
- The impact of cytomegalovirus coinfection on tuberculosis in the mouse model.BMC infectious diseases · 2026Article
- Molecular signaling in coinfection: howFrontiers in immunology · 2026Review
- Article
- Impact of cytomegalovirus exposure on disease severity, bacterial burden, immune responses and treatment outcomes in tuberculosis.Frontiers in immunology · 2025Article
- Mycobacterium tuberculosis infection and tuberculosis disease in the first decade of life: a South African birth cohort study.The Lancet. Child & adolescent health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tuberculosis (TB) is a leading cause of mortality from an infectious disease. In this opinion article, we focus on accumulating scientific evidence indicating that viral infections may contribute to TB progression, possibly allowing novel preventive interventions. Viruses can remodel the mammalian immune system, potentially modulating the risk of reactivating latent microbes such as Mycobacterium tuberculosis (Mtb). Evidence is mixed regarding the impact of emergent viruses such as SARS-CoV-2 on the risk of TB. Therefore, we posit that important knowledge gaps include elucidating which viral families increase TB risk and whether these provide unique or shared immune mechanisms. We also propose potential future research to define the contribution of viruses to TB pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.